Neuroendocrine functions, mood and quality of life

  • Marianna Mazza
  • Salvatore Mazza


The neuroendocrine system and the distribution of hormones through the brain and their modulatory role and influence in behaviour and mood have been studied for a long time. The most evident changes associated with mood disorders are in the hypothalamic-pituitary-adrenal (HPA), the hypothalamic-pituitary-thyroid (HPT), the hypothalamic-pituitary-GH (HPGH) and the hypothalamic-pituitary-gonadal (HPGn) axes. Hypotheses referring to the psychophysiological meaning and the development of these alterations are discussed. In order to improve the quality of life for patients suffering from mood disorders, it would be important to define which specific hormonal axes contribute to mood symptoms and which medications that normalize neuroendocrine function are conditioning the impact of mood symptoms. The identification and detailed characterization of these pathways will ultimately lead to the development of novel neuropharmacological intervention strategies. Future directions for research are described.

All data derived from studies focusing on central neuropeptidergic circuits and peripheral hormone systems add to the understanding of the pathophysiology of mood disorders and indicate the importance of investigating neuroendocrine dysfunctions in psychiatric patients both to ensure proper diagnosis and adequate pharmacotherapies

Key words

Neuroendocrinology Neuroendocrine System Mood Depression Bipolar Disorder Quality of life 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ritsner M, Modai I, Endicott J, et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 2000; 61 (11): 880–889.PubMedCrossRefGoogle Scholar
  2. 2.
    Ritsner M, Kurs R. Quality of life outcomes in mental illness: schizophrenia, mood and anxiety disorders. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3 (2): 89–99.CrossRefGoogle Scholar
  3. 3.
    Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hops Com Psychiatry 1992; 43: 262–265.Google Scholar
  4. 4.
    Ritsner M, Kurs R, Gibel A, et al. Predictors of quality of life in major psychoses: a naturalistic follow-up study. J Clin Psychiatry 2003; 64 (3): 308–315.PubMedCrossRefGoogle Scholar
  5. 5.
    Ritsner M. Predicting changes in domain-specific quality of life of schizophrenia patients. J Nerv Ment Dis 2003; 191: 287–294.PubMedCrossRefGoogle Scholar
  6. 6.
    Ritsner M, Ben-Avi I, Ponizovsky A, et al. Quality of life and coping with schizophrenic symptoms. Quality of Life Res 2003; 12: 1–9.CrossRefGoogle Scholar
  7. 7.
    Ritsner M, Gibel A, Ratner Y. Determinants of changes in perceived quality of life in the course of schizophrenia. Quality of Life Res 2006; 16: 515–526.CrossRefGoogle Scholar
  8. 8.
    Rasgon NL. Anatomic, functional, and clinical studies of neuroendocrine function in bipolar disorder. Adv. Stud. Med 2003; 3 (8A): S726–732.Google Scholar
  9. 9.
    Kaplan HI, Sadock BJ, Grebb JA. Psichiatria: manuale di scienze del comportamento e psichiatria clinica (VII Ed), CSI, Torino, 1996.Google Scholar
  10. 10.
    Mazza M, Satta MA, Bria P, Mazza S. Neuroendocrinology of mood disorders. Clin Ter 2004; 155 (11-12): 537–541.PubMedGoogle Scholar
  11. 11.
    Loosen PT. The TRH-induced TSH response in psychiatric patients: a possible neuroendocrine marker. Psychoneuroendocrinology 1985; 10:237–260.PubMedCrossRefGoogle Scholar
  12. 12.
    Duval F, Macher JP, Mokrani MC. Difference between evening and morning thyrotropin responses to protirelin in major depressive episode. Arch of Gen Psychiatry 1990; 47: 443–448.Google Scholar
  13. 13.
    Kirkegaard C, Faber J, Hummer L, et al. Increased levels of TRH in cerebrospinal fluid from patients with endogenous depression. Psychoneuroendocrinology 1979; 4: 227–235.PubMedCrossRefGoogle Scholar
  14. 14.
    Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Archives of General Psychiatry 1993, 50: 387–393.PubMedGoogle Scholar
  15. 15.
    Siever LJ, Davis KL. Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry 1985; 142: 1017–1031.PubMedGoogle Scholar
  16. 16.
    Trestman RL, Yehuda R, Coccaro E, et al. Diurnal neuroendocrine and autonomic function in acute and remitted depressed male patients. Biological Psychiatry 1995; 37:448–456.PubMedCrossRefGoogle Scholar
  17. 17.
    Ehlert U, Gaab J, Heinrichs M. Psychoneuroendocrinological contributions to the etiology of depression, posttraumtic stress disorder, and stress-related bodily disorders: the role of the hypothalamus-pituitary-adrenal axis. Biol Psychology 2001; 57: 141–152.CrossRefGoogle Scholar
  18. 18.
    Burke HM, Davis MC, Otte C, et al. Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinol 2005; 30: 846–856.CrossRefGoogle Scholar
  19. 19.
    Holsboer F. Stress, hypercortisolism and cosrticosteroid receptors in depression: implications for therapy. J Affect Disord 2001; 62: 77–91.PubMedCrossRefGoogle Scholar
  20. 20.
    Otte C, Hart S, Neylan TC, et al. A meta-analysis of glucocorticoid reactivity in human aging: implications for Alzheimer’s disease and depression. Psychoneuroendocrinol 2005; 30: 80–91.CrossRefGoogle Scholar
  21. 21.
    Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003; 160: 1554–1565.PubMedCrossRefGoogle Scholar
  22. 22.
    Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 2005; 66(7): 5–13.Google Scholar
  23. 23.
    Holsboer F. The corticosteroid hypothesis of depression. Neuropsychopharmacol 2000; 23: 477–501.CrossRefGoogle Scholar
  24. 24.
    Zobel AW, Nickel T, Sonntag A, et al. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J Psychiatr Res 2001; 35: 83–94.PubMedCrossRefGoogle Scholar
  25. 25.
    Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 391–404.PubMedCrossRefGoogle Scholar
  26. 26.
    O’Connor TM, O’Halloran DJ, Shanahan F. The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia. Q J Med 2000; 93: 323–333.Google Scholar
  27. 27.
    Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression: relationship to the neurobiology of stress. N Engl J Med 1988; 319: 348–353.PubMedCrossRefGoogle Scholar
  28. 28.
    Pariante CM, Pearce BD, Pisell TL, et al. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 1997; 52:571–581.PubMedGoogle Scholar
  29. 29.
    Belanoff JK, Flores BH, Kalezhan M, et al. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001; 21: 516–521.PubMedCrossRefGoogle Scholar
  30. 30.
    Young AH. Cortisol in mood disorders. Stress 2004; 7(4): 205–208.CrossRefGoogle Scholar
  31. 31.
    Holsboer F. Corticotropin-releasing hormone modulators and depression. Curr Opin Investig Drugs 2003; 4(1): 46–50.Google Scholar
  32. 32.
    Yuuki M, Ida I, Oshima A, et al. HPA axis normalization, estimated by DEX/CRH test, but less alteration on cerebral glucose metabolism in depressed patients receiving ECT after medication treatment failures. Acta Psychiatr Scand 2005; 112: 257–265.PubMedCrossRefGoogle Scholar
  33. 33.
    Pfennig A, Kunzel HE, Kern N. Hypothalamus-pituitary-adrenal system regulation and suicidal behaviour in depression. Biol Psychiatry 2005; 57: 336–342.PubMedCrossRefGoogle Scholar
  34. 34.
    Nemeroff CB, Owens MJ, Bissette G, et al. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988; 45: 577–579.PubMedGoogle Scholar
  35. 35.
    Goodyer IM, Park RJ, Netherton CM, et al. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. Br J Psychiatry 2001; 179: 243–249.PubMedCrossRefGoogle Scholar
  36. 36.
    Birmaher B, Dahl RE, Perel J. Corticotropin-releasing hormone challenge in prepuberal major depression. Biol Psychiatry 1996; 39: 267–277.PubMedCrossRefGoogle Scholar
  37. 37.
    Goodyer IM, Altham PME. Short term outcome of major depression. A high cortisol/DHEA ratio and subsequent disappointing life events predict persistent depression. Psychol Med 1997; 28: 265–273.CrossRefGoogle Scholar
  38. 38.
    Goodyer IM, Tamplin A. Recent life events, cortisol, dehydroepiandrosterone and the onset of major depression high-risk adolescents. Br J Psychiatry 2000; 177: 499–504.PubMedCrossRefGoogle Scholar
  39. 39.
    Rush AJ, Giles DE, Schlesser MA, et al. Dexamethasone response, thyrotropin releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol Psychiatry 1997; 41(9):915–928.PubMedCrossRefGoogle Scholar
  40. 40.
    Mokrani MC, Bailey P. Thyroid axis activity and serotonin function in major depressive episode. Psychoneuroendocrinol 1999; 24: 695–712.CrossRefGoogle Scholar
  41. 41.
    Mokrani MC, Duval F, Crocq MA, et al. HPA axis dysfunction in depression: correlation with monoamine system abnormalities. Psychoneuroendocrinol 1997; 22 (Suppl 1), S63–S68.Google Scholar
  42. 42.
    Dinan TG. Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br J Psychiatry 1994; 164: 365–371.PubMedGoogle Scholar
  43. 43.
    Esel E, Kartalci S, Tutus A, et al. Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients. Progr in Neuropsychopharmacol and Biol Psychiatry 2004; 28: 303–309.CrossRefGoogle Scholar
  44. 44.
    Peteranderl C, Antonijevic IA, Steiger A, et al. Nocturnal secretion of TSH and ACTH in male patients with depression and healthy controls. J Psychiatric Research 2002; 36: 189–196.CrossRefGoogle Scholar
  45. 45.
    Sullivan PF, Wilson DA, Mulder RT, et al. The hypothalamic-pituitary-thyroid axis in major depression. Acta Psychiatrica Scandinavica 1997; 95: 370–378.PubMedGoogle Scholar
  46. 46.
    Engum A, Bjoro T, Mykletun A, et al. An association between depression, anxiety and thyroid function: a clinical fact or an artefact? Acta Psychiatrica Scandinavica 2002; 106:27–34.PubMedCrossRefGoogle Scholar
  47. 47.
    Demet MM, Ozmen B, Deveci A, et al. Depression and anxiety in hyperthyroidism. Archives of Medical Research 2002; 33: 552–556.PubMedCrossRefGoogle Scholar
  48. 48.
    Cooke RG, Joffe RT, Levitt AJ. T3 augmentation of antidepressant treatment in T4-replaced thyroid patients. J Clin Psychiatry 1992; 53: 16–18.PubMedGoogle Scholar
  49. 49.
    Sawka AM, Gerstein HC, Marriott MJ. Does a combination regimen of Thyroxine (T4) and 3,5,3’-Triiodothyronine improve depressive symptoms better tha T4 alone in patients with Hypothyroidism? Results of a double-blind, randomised, controlled trial. J Clin Endocrinol Metab 2003; 88(10): 4551–4555.CrossRefGoogle Scholar
  50. 50.
    Degner D, Meller J, Bleich S, et al. Affective disorders associated with autoimmune thyroiditis. J Neuropsychiatry Clin Neurosci 2001; 13: 4, 532–533.PubMedGoogle Scholar
  51. 51.
    Isogawa K, Nagayama H, Tsutsumi T, et al. Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropine-releasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder. J Psy Research 2005; 39: 467–473.CrossRefGoogle Scholar
  52. 52.
    Shively CA, Bethea CL. Cognition, mood disorders and sex hormones. ILAR Journal 2004; 45(2): 189–199.PubMedGoogle Scholar
  53. 53.
    Steiner M, Dunn E, Born L. Hormones and mood: from menarche to menopause and beyond. J Affective Disorders 2003; 74: 67–83.CrossRefGoogle Scholar
  54. 54.
    Steiner M, Born L. Advances in the diagnosis and treatment of premenstrual dysphoria. CNS Drugs 2000; 13: 286–304.CrossRefGoogle Scholar
  55. 55.
    Bloch M, Daly RC, Rubinow DR. Endocrine factors in the etiology of postpartum depression. Compr Psychiatry 2003; 44 (3): 234–246.PubMedCrossRefGoogle Scholar
  56. 56.
    Bao AM, Hestiantoro A, Van Someren EJW, et al. Colocalization of corticotropin-releasing hormone and oestrogen receptor- in the paraventricular nucleus of the hypothalamus in mood disorders. Brain 2005; 128: 1301–1313.PubMedCrossRefGoogle Scholar
  57. 57.
    Swaab DF, Fliers E, Hoogendijk WJ, et al. Interaction of prefrontal cortical and hypothalamic systems in the pathogenesis of depression. Progr Brain Res 2000; 126: 369–396.Google Scholar
  58. 58.
    Meyer-Bahlburg HFL, Ehrhardt AA. A prenatal-hormone hypothesis for depression in adults with a history of fetal DES exposure. In: Halbreich U, editor. Hormones and depression. New York: Raven Press; 1987: 325–338.Google Scholar
  59. 59.
    Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 2001; 15(10): 797–817.PubMedCrossRefGoogle Scholar
  60. 60.
    Carnahan RM, Perry PJ. Depression in aging men. Drugs Aging 2004: 21(6): 361–376.PubMedCrossRefGoogle Scholar
  61. 61.
    Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005; 4: 141–194.PubMedCrossRefGoogle Scholar
  62. 62.
    Tichomirowa MA, Keck ME, Schneider HJ, et al. Endocrine disturbances in depression. J Endocrinol Invest 2005; 28: 89–99.PubMedGoogle Scholar
  63. 63.
    Spinelli MG. Neuroendocrine effects on mood. Rev Endocr Metab Disord 2005; 6(2): 109–115.PubMedCrossRefGoogle Scholar
  64. 64.
    Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secetion comes of age. Front Neuroendocrinol 1993; 14: 76–122.PubMedCrossRefGoogle Scholar
  65. 65.
    van Londer L, Goekoop JG, van Kempen GM. Palsma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacol 1997; 17: 284–292.CrossRefGoogle Scholar
  66. 66.
    Griebel G, Sirniand J, Serradeil-Le Gal C. Anxiolotic and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 2002; 99: 6370–6375.Google Scholar
  67. 67.
    Keck ME, Welt T, Muller MB. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacol 2003; 28: 235–243.CrossRefGoogle Scholar
  68. 68.
    Zhou JN, Riernersma RF, Unmehopa UA. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 2001; 58: 655–662.PubMedCrossRefGoogle Scholar
  69. 69.
    Inder WJ, Donald RA, Prickett TCR, et al. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol Psychiatry 1997; 42: 744–747.PubMedCrossRefGoogle Scholar
  70. 70.
    Mazza M, Della Marca G, Paciello N, et al. Orexin, sleep and appetite regulation: a review. Clin Ter 2005; 156(3): 93–96.PubMedGoogle Scholar
  71. 71.
    Della Marca G, Farina B, Mennuni GF, et al. Microstructure of Sleep in Eating Disorders: Preliminary Results, J Eating and Weight Disorders 2004; 9: 77–80.Google Scholar
  72. 72.
    Deuschle M, Blum WF, Englaro P. Palsma leptin in depressed patients and healthy controls. Horm Metab Res 1996; 29: 714–717.CrossRefGoogle Scholar
  73. 73.
    Antonijevic IA, Murck H, Frieboes RM, et al. Elevated nocturnal profiles of serum leptin in patients with depression. J Psychiatr Res 1998;32: 403–410.PubMedCrossRefGoogle Scholar
  74. 74.
    Schmider J, Lammers CH, Gotthardt U, et al. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression and in normal controls. Biol Psychiatry, 1995; 38:797–802.Google Scholar
  75. 75.
    Watson S, Gallagher P, Ritchie JC, et al. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004; 184: 496–502.PubMedCrossRefGoogle Scholar
  76. 76.
    Linkowski P, Brauman H, Mendlewicz J. Thyrotropin response to thyrotropin-releasing hormone in unipolar and bipolar affective illness. J affect Disorders 1981; 3: 9–16.PubMedCrossRefGoogle Scholar
  77. 77.
    Matsunaga H, Sarai M. Elevated serum LH and androgens in affective disorder related to the menstrual cycle with referrence to polycystic ovary syndrome. Jpn J Psychiatry Neurol 1993; 47: 825–842.PubMedGoogle Scholar
  78. 78.
    Sobczak S, Honig A, van Duinen MA, et al. Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies. Bipolar Disorders 2002; 4: 347–356.PubMedCrossRefGoogle Scholar
  79. 79.
    Sassi RB, Nicoletti M, Brambilla P, et al. Decreased Pituitary volume in patients with bipolar disorder. Biol Psychiatry 2001; 50: 271–280.PubMedCrossRefGoogle Scholar
  80. 80.
    O’Donovan C, Kusumakar V, Graves GR, et al. Menstrual abnormalities in polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002 ; 63: 322–330.PubMedGoogle Scholar
  81. 81.
    Gilmor ML, Skelton KH, Nemeroff CB, et al. The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. JPET 2003; 305: 434–439.CrossRefGoogle Scholar
  82. 82.
    Rasgon NL, Harden CL. Neuroendocrine dysfunction in women with epilepsy or bipolar disorder: implications for patient management. Adv Stud Med 2003; 3(8A): S740-S744.Google Scholar
  83. 83.
    Isojarvi JI, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 597–584.CrossRefGoogle Scholar
  84. 84.
    Bartalena L, Pellegrini L, Meschi M, et al. Evaluation of thyroid function in patients with rapid-cycling and non-rapid-cycling bipolar disorder. Psychiatry Research 1990; 34: 13–17.PubMedCrossRefGoogle Scholar
  85. 85.
    Kusalic M. Grade II and grade III hypothyroidism in rapid-cycling bipolar patients. Neuropsychobiology 1992; 25: 177–181.PubMedCrossRefGoogle Scholar
  86. 86.
    Post RM, Kramlinger KG, Joffe RT, et al. Rapid cycling bipolar affective disorder: lack of relation to hypothyroidism. Psychiatry Research 1997; 72: 1–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47: 435–440.Google Scholar
  88. 88.
    Gyulai L, Bauer M, Bauer MS, et al. Thyroid hypofunction in patients with rapid-cycling bipolar disorder after lithium challenge. Biological Psychiatry 2003; 53: 899–905.PubMedCrossRefGoogle Scholar
  89. 89.
    Bauer M, Whybrow PC. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry 2001; 2(2): 59–69.PubMedCrossRefGoogle Scholar
  90. 90.
    Cole DP, Thase ME, Mallinger AG, et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry 2002; 159: 116–121.PubMedCrossRefGoogle Scholar
  91. 91.
    Cervantes P, Gelber S, Kin F, et al. Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci 2001; 26 (5): 411–416.PubMedGoogle Scholar
  92. 92.
    Daban C, Vieta E, Mackin P, et al. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005; 28(2): 469–480.PubMedCrossRefGoogle Scholar
  93. 93.
    Ozkan S, Alatas E, Zencir M. Women’s quality of life in the premenopausal and post menopausal periods. Qual Life Res 2005; 14: 1795–1801.PubMedCrossRefGoogle Scholar
  94. 94.
    Almeida OP, Lautenschlager NT, Vasikaran S, et al. A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiol Aging 2006; 27: 141–149.PubMedCrossRefGoogle Scholar
  95. 95.
    Halbreich U, Borenstein J, Pearlstein T, et al. The prevalence, impairment, impact and burden of premenstrual dysphoric disorder. Psychoneuroendocrinol 2003; 28: 1–23.Google Scholar
  96. 96.
    Arwert LI, Deijen JB, Muller M, et al. Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Hormones Behav 2005; 47: 343–349.CrossRefGoogle Scholar
  97. 97.
    Stouthart PJHM, Deijen JB, Roffel M, et al. Quality of life of growth hormone deficient young adults during discontinuation and restart of GH therapy. Psychoneuroendocrinol 2003; 28: 612–626.CrossRefGoogle Scholar
  98. 98.
    Haren MT, Wittert GA, Chapman IM, et al. Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas 2005; 50: 124–133.PubMedCrossRefGoogle Scholar
  99. 99.
    Delhez M, Hansenne M, Legros JJ. Andropause and psychopathology: minor symptoms rather than pathological ones. Psychoneuroendocrinol 2003; 28: 863–874.CrossRefGoogle Scholar
  100. 100.
    Fahrenfort JJ, Wilterdink AML, van der Veen EA. Long-term residual complaints and psychosocial sequelae after remission of hyperthyrioidism. Psychoneuroendocrinol 2000; 25: 201–211.CrossRefGoogle Scholar
  101. 101.
    Coker LH, Kashemi R, Cantley L, et al. Primary hyperparathyroidism, cognition, and health-related quality of life. Annals of Surgery 2005; 242 (5): 642–650.PubMedCrossRefGoogle Scholar
  102. 102.
    Bianchi GP, Zaccheroni V, Solaroli E, et al. Health-related quality of life in patients with thyroid disorders. Qual Life Res 2004; 13 (1): 45–54.PubMedCrossRefGoogle Scholar
  103. 103.
    Robb JC, Cooke RG, Devins GM, et al. Quality of life and lifestyle disruption in euthymic bipolar disorder. J Psychiatr Res 1997; 31 (5): 509–517.PubMedCrossRefGoogle Scholar
  104. 104.
    Vojta C, Kinosian B, Glick H, et al. Self-reported quality of life across mood states in bipolar disorder. Compr Psychiatry 2001; 42 (3): 190–195.PubMedCrossRefGoogle Scholar
  105. 105.
    Kasper SF. Living with bipolar disorder. Expert Rev Neurotherapeutics 2004; 4 (6 Suppl 2): 9–15.CrossRefGoogle Scholar
  106. 106.
    Marangell LB. Thyroid hormones and mood: are population data applicable to clinical cohorts? Acta Psychiatrica Scandinavica 2002; 106: 1–2.PubMedCrossRefGoogle Scholar
  107. 107.
    Duval F, Mokrani MC, Bailey P, et al. Thyroid axis activity and serotonin function in major depressive episode. Psychoneuroendocrinology 1999; 24: 695–712.PubMedCrossRefGoogle Scholar
  108. 108.
    Mazza M, Della Marca G, Mennuni GF, et al. Sleep disturbances and depression: a review. Minerva Psichiatr 2005; 46: 175–188.Google Scholar

Copyright information

© springer 2007

Authors and Affiliations

  • Marianna Mazza
    • 1
  • Salvatore Mazza
    • 2
  1. 1.Institute of PsychiatryCatholic University of Sacred HeartRomeIsrael
  2. 2.Department of NeurosciencesCatholic University of Sacred HeartRomeIsrael

Personalised recommendations